Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Net income
Charles River Laboratories International, Inc.'s net income for fiscal 2025 was −$142.2M, compared with $25.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$236.3M. Over the past ten years it has ranged from −$142.2M (fiscal 2025) to $492.6M (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 50th of 52 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$142.2M | — |
| FY2024 | $25.3M | (94.74%) |
| FY2023 | $480.4M | (2.48%) |
| FY2022 | $492.6M | 23.51% |
| FY2021 | $398.8M | 9.18% |
| FY2020 | $365.3M | 43.79% |
| FY2019 | $254.1M | 11.08% |
| FY2018 | $228.7M | 82.32% |
| FY2017 | $125.4M | (19.77%) |
| FY2016 | $156.4M | 3.49% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$760.0K | — |
| Mar 2026 | −$14.8M | — |
| Dec 2025 | −$276.3M | — |
| Sep 2025 | $55.6M | 5.43% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.1B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MEDP Medpace Holdings, Inc. compare | $491.5M |
| QGEN QIAGEN N.V. compare | $409.3M |
| RVTY Revvity Inc. compare | $237.6M |
| ICLR ICON PLC compare | $42.3M |
| TWST Twist Bioscience Corporation compare | −$136.7M |
| CRL Charles River Laboratories International, Inc. | −$236.3M |
| GH Guardant Health, Inc. compare | −$453.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on CRL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement